Schizophrenia Research
Volume 117, Issue 1 , Pages 83-91 , March 2010

GABA concentration in schizophrenia patients and the effects of antipsychotic medication: A proton magnetic resonance spectroscopy study

  • Shin'Ya Tayoshi

      Affiliations

    • Department of Psychiatry, Course of Integrated Brain Sciences, Medical Informatics, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
    • ,
  • Masahito Nakataki

      Affiliations

    • Department of Psychiatry, Course of Integrated Brain Sciences, Medical Informatics, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
    • Corresponding Author InformationCorresponding author. Department of Psychiatry, Course of Integrated Brain Sciences, Medical Informatics, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-8-15 Kuramoto-cho Tokushima 770-8503, Japan. Tel.: +81 88 633 7130; fax: +81 88 633 7131.
    • ,
  • Satsuki Sumitani

      Affiliations

    • Department of Psychiatry, Course of Integrated Brain Sciences, Medical Informatics, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
    • ,
  • Kyoko Taniguchi

      Affiliations

    • Department of Psychiatry, Course of Integrated Brain Sciences, Medical Informatics, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
    • ,
  • Sumiko Shibuya-Tayoshi

      Affiliations

    • Department of Psychiatry, Course of Integrated Brain Sciences, Medical Informatics, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
    • ,
  • Shusuke Numata

      Affiliations

    • Department of Psychiatry, Course of Integrated Brain Sciences, Medical Informatics, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
    • ,
  • Jun-ichi Iga

      Affiliations

    • Department of Psychiatry, Course of Integrated Brain Sciences, Medical Informatics, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
    • ,
  • Shu-ichi Ueno

      Affiliations

    • Department of Neuropsychiatry, Neuroscience, Ehime University Graduate School of Medicine, Japan
    • ,
  • Masafumi Harada

      Affiliations

    • Department of Radiology, Major in Radiology, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
    • ,
  • Tetsuro Ohmori

      Affiliations

    • Department of Psychiatry, Course of Integrated Brain Sciences, Medical Informatics, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan

Received 17 November 2008 ,Revised 18 November 2009 ,Accepted 21 November 2009.

References 

  1. Abi-Dargham A, Laruelle M, Krystal J, D'Souza C, Zoghbi S, Baldwin RM, et al. No evidence of altered in vivo benzodiazepine receptor binding in schizophrenia. Neuropsychopharmacology. 1999;20(6):650–661
  2. Akil M, Kolachana BS, Rothmond DA, Hyde TM, Weinberger DR, Kleinman JE. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J. Neurosci. 2003;23(6):2008–2013
  3. Asai Y, Takano A, Ito H, Okubo Y, Matsuura M, Otsuka A, et al. GABAA/benzodiazepine receptor binding in patients with schizophrenia using [11C]Ro15-4513, a radioligand with relatively high affinity for alpha5 subunit. Schizophr. Res. 2008;99(1–3):333–340
  4. Baiano M, David A, Versace A, Churchill R, Balestrieri M, Brambilla P. Anterior cingulate volumes in schizophrenia: a systematic review and a meta-analysis of MRI studies. Schizophr. Res. 2007;93(1–3):1–12
  5. Ball S, Busatto GF, David AS, Jones SH, Hemsley DR, Pilowsky LS, et al. Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: a 123I-iomazenil SPET study. Biol. Psychiatry. 1998;43(2):107–117
  6. Benes FM, Vincent SL, Alsterberg G, Bird ED, SanGiovanni JP. Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics. J. Neurosci. 1992;12(3):924–929
  7. Benes FM, Todtenkopf MS, Logiotatos P, Williams M. Glutamate decarboxylase(65)-immunoreactive terminals in cingulate and prefrontal cortices of schizophrenic and bipolar brain. J. Chem. Neuroanat. 2000;20(3–4):259–269
  8. Bird ED, Spokes EG, Barnes J, MacKay AV, Iversen LL, Shepherd M. Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses. Lancet. 1977;2(8049):1157–1158
  9. Bolam JP, Hanley JJ, Booth PA, Bevan MD. Synaptic organisation of the basal ganglia. J. Anat. 2000;196(Pt 4):527–542
  10. Brüne M, Lissek S, Fuchs N, Witthaus H, Peters S, Nicolas V, et al. An fMRI study of theory of mind in schizophrenic patients with “passivity” symptoms. Neuropsychologia. 2008;46(7):1992–2001
  11. Busatto GF, Pilowsky LS, Costa DC, Ell PJ, David AS, Lucey JV, et al. Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. Am. J. Psychiatry. 1997;154(1):56–63
  12. Bustillo JR, Lauriello J, Rowland LM, Jung RE, Petropoulos H, Hart BL, et al. Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. Psychiatry Res. 2001;107(3):135–149
  13. Calabresi P, Centonze D, Gubellini P, Pisani A, Bernardi G. Acetylcholine-mediated modulation of striatal function. Trends Neurosci. 2000;23(3):120–126
  14. Carlsson A. A paradigm shift in brain research. Science. 2001;294(5544):1021–1024
  15. Chen JF, Weiss B. Irreversible blockade of D2 dopamine receptors by fluphenazine-N-mustard increases glutamic acid decarboxylase mRNA in rat striatum. Neurosci. Lett. 1993;150(2):215–218
  16. Choe BY, Suh TS, Shinn KS, Lee CW, Lee C, Paik IH. Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. Invest. Radiol. 1996;31(6):345–352
  17. Choi I, Lee S, Merkle H, Shen J. In vivo detection of gray and white matter differences in GABA concentration in the human brain. Neuroimage. 2006;33(1):85–93
  18. Delfs JM, Anegawa NJ, Chesselet MF. Glutamate decarboxylase messenger RNA in rat pallidum: comparison of the effects of haloperidol, clozapine and combined haloperidol-scopolamine treatments. Neuroscience. 1995;66(1):67–80
  19. Delfs JM, Ellison GD, Mercugliano M, Chesselet MF. Expression of glutamic acid decarboxylase mRNA in striatum and pallidum in an animal model of tardive dyskinesia. Exp. Neurol. 1995;133(2):175–188
  20. Dracheva S, Elhakem SL, McGurk SR, Davis KL, Haroutunian V. GAD67 and GAD65 mRNA and protein expression in cerebrocortical regions of elderly patients with schizophrenia. J. Neurosci. Res. 2004;76(4):581–592
  21. Epperson CN, O'Malley S, Czarkowski KA, Gueorguieva R, Jatlow P, Sanacora G, et al. Sex, GABA, and nicotine: the impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy. Biol. Psychiatry. 2005;57(1):44–48
  22. Fujiwara H, Hirao K, Namiki C, Yamada M, Shimizu M, Fukuyama H, et al. Anterior cingulate pathology and social cognition in schizophrenia: a study of gray matter, white matter and sulcal morphometry. Neuroimage. 2007;36(4):1236–1245
  23. Galeno R, Molina M, Guirao M, Isoardi R. Severity of negative symptoms in schizophrenia correlated to hyperactivity of the left globus pallidus and the right claustrum. A PET study. World J. Biol. Psychiatry. 2004;5(1):20–25
  24. Goff DC, Hennen J, Lyoo IK, Tsai G, Wald LL, Evins AE, et al. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol. Psychiatry. 2002;51(6):493–497
  25. Graybiel AM. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 1990;13(7):244–254
  26. Guidotti A, Auta J, Davis JM, Dong E, Grayson DR, Veldic M, et al. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology (Berl.). 2005;180(2):191–205
  27. Gunne LM, Häggström JE, Sjöquist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature. 1984;309(5966):347–349
  28. Hanada S, Mita T, Nishino N, Tanaka C. [3H]muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sci. 1987;40(3):259–266
  29. Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 2007;64(2):193–200
  30. Hasler G, Nugent AC, Carlson PJ, Carson RE, Geraci M, Drevets WC. Altered cerebral gamma-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by [11C]flumazenil positron emission tomography. Arch. Gen. Psychiatry. 2008;65(10):1166–1175
  31. Ishikawa M, Mizukami K, Iwakiri M, Hidaka S, Asada T. Immunohistochemical and immunoblot study of GABA(A) alpha1 and beta2/3 subunits in the prefrontal cortex of subjects with schizophrenia and bipolar disorder. Neurosci. Res. 2004;50(1):77–84
  32. Izzo PN, Bolam JP. Cholinergic synaptic input to different parts of spiny striatonigral neurons in the rat. J. Comp. Neurol. 1988;269(2):219–234
  33. Johnson AE, Liminga U, Lidén A, Lindefors N, Gunne LM, Wiesel FA. Chronic treatment with a classical neuroleptic alters excitatory amino acid and GABAergic neurotransmission in specific regions of the rat brain. Neuroscience. 1994;63(4):1003–1020
  34. Jolkkonen J, Jenner P, Marsden CD. GABAergic modulation of striatal peptide expression in rats and the alterations induced by dopamine antagonist treatment. Neurosci. Lett. 1994;180(2):273–276
  35. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13(2):261–276
  36. Koch K, Wagner G, Nenadic I, Schachtzabel C, Schultz C, Roebel M, et al. Fronto-striatal hypoactivation during correct information retrieval in patients with schizophrenia: an fMRI study. Neuroscience. 2008;153(1):54–62
  37. Laprade N, Soghomonian JJ. Differential regulation of mRNA levels encoding for the two isoforms of glutamate decarboxylase (GAD65 and GAD67) by dopamine receptors in the rat striatum. Brain Res. Mol. Brain Res. 1995;34(1):65–74
  38. Lee K, Brown WH, Egleston PN, Green RDJ, Farrow TFD, Hunter MD, et al. A functional magnetic resonance imaging study of social cognition in schizophrenia during an acute episode and after recovery. Am. J. Psychiatry. 2006;163(11):1926–1933
  39. Liddle PF, Laurens KR, Kiehl KA, Ngan ETC. Abnormal function of the brain system supporting motivated attention in medicated patients with schizophrenia: an fMRI study. Psychol. Med. 2006;36(8):1097–1108
  40. Meda SA, Giuliani NR, Calhoun VD, Jagannathan K, Schretlen DJ, Pulver A, et al. A large scale (N=400) investigation of gray matter differences in schizophrenia using optimized voxel-based morphometry. Schizophr. Res. 2008;101(1–3):95–105
  41. Menzies L, Ooi C, Kamath S, Suckling J, McKenna P, Fletcher P, et al. Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. Arch. Gen. Psychiatry. 2007;64(2):156–167
  42. Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R. Simultaneous in vivo spectral editing and water suppression. NMR Biomed. 1998;11(6):266–272
  43. Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia. 1971;9(1):97–113
  44. Pandey GN, Conley RR, Pandey SC, Goel S, Roberts RC, Tamminga CA, et al. Benzodiazepine receptors in the post-mortem brain of suicide victims and schizophrenic subjects. Psychiatry Res. 1997;71(3):137–149
  45. Perlman WR, Weickert CS, Akil M, Kleinman JE. Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes. J Psychiatry Neurosci. 2004;29(4):287–293
  46. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993;30(6):672–679
  47. Sakai K, Gao XM, Hashimoto T, Tamminga CA. Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways. Synapse. 2001;39(2):152–160
  48. Sharp FR, Butman M, Aardalen K, Nickolenko J, Nakki R, Massa SM, et al. Neuronal injury produced by NMDA antagonists can be detected using heat shock proteins and can be blocked with antipsychotics. Psychopharmacol. Bull. 1994;30(4):555–560
  49. Sharp FR, Tomitaka M, Bernaudin M, Tomitaka S. Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia?. Trends Neurosci. 2001;24(6):330–334
  50. Spinks R, Nopoulos P, Ward J, Fuller R, Magnotta VA, Andreasen NC. Globus pallidus volume is related to symptom severity in neuroleptic naive patients with schizophrenia. Schizophr. Res. 2005;73(2–3):229–233
  51. Squires RF, Saederup E. Additivities of compounds that increase the numbers of high affinity [3H]muscimol binding sites by different amounts define more than 9 GABA(A) receptor complexes in rat forebrain: implications for schizophrenia and clozapine research. Neurochem. Res. 2000;25(12):1587–1601
  52. Squires RF, Lajtha A, Saederup E, Palkovits M. Reduced [3H]flunitrazepam binding in cingulate cortex and hippocampus of postmortem schizophrenic brains: is selective loss of glutamatergic neurons associated with major psychoses?. Neurochem. Res. 1993;18(2):219–223
  53. Szulc A, Galinska B, Tarasow E, Dzienis W, Kubas B, Konarzewska B, et al. The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS). Pharmacopsychiatry. 2005;38(5):214–219
  54. Tayoshi S, Sumitani S, Taniguchi K, Shibuya-Tayoshi S, Numata S, Iga J, et al. Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). Schizophr. Res. 2009;108(1–3):69–77
  55. Verhoeff NP, Soares JC, D'Souza CD, Gil R, Degen K, Abi-Dargham A, et al. [123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Res. 1999;91(3):163–173
  56. Vincent SL, Adamec E, Sorensen I, Benes FM. The effects of chronic haloperidol administration on GABA-immunoreactive axon terminals in rat medial prefrontal cortex. Synapse. 1994;17(1):26–35
  57. Wassef A, Baker J, Kochan LD. GABA and schizophrenia: a review of basic science and clinical studies. J. Clin. Psychopharmacol. 2003;23(6):601–640
  58. Woo TW, Walsh JP, Benes FM. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch. Gen. Psychiatry. 2004;61(7):649–657
  59. Woo TW, Kim AM, Viscidi E. Disease-specific alterations in glutamatergic neurotransmission on inhibitory interneurons in the prefrontal cortex in schizophrenia. Brain Res. 2008;1218:267–277
  60. Yücel M, Brewer WJ, Harrison BJ, Fornito A, O'Keefe GJ, Olver J, et al. Anterior cingulate activation in antipsychotic-naïve first-episode schizophrenia. Acta Psychiatr. Scand. 2007;115(2):155–158
  61. Zetzsche T, Preuss U, Frodl T, Watz D, Schmitt G, Koutsouleris N, et al. In-vivo topography of structural alterations of the anterior cingulate in patients with schizophrenia: new findings and comparison with the literature. Schizophr. Res. 2007;96(1–3):34–45
  62. Zink M, Schmitt A, May B, Müller B, Demirakca T, Braus DF, et al. Differential effects of long-term treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression. Schizophr. Res. 2004;66(2–3):151–157

PII: S0920-9964(09)00562-3

doi: 10.1016/j.schres.2009.11.011

Schizophrenia Research
Volume 117, Issue 1 , Pages 83-91 , March 2010

Article Tools

* Image Usage & Resolution